
Kevin Xu
CEO at MEBO International
Kevin Xu is the CEO of MEBO International, a California and Beijing based intellectual property Management Company responsible for managing “Human Body Regenerative Restoration Science” (HBRRS). CEO of Skingenix, California based Company exclusively working on drug development in the field of damaged organ regeneration. Founder of MEBO campus, a virtual educational platform for organ regeneration science. He is a member of the Young Entrepreneur Council (YEC), an appointee of the California-China Trade and Investment Advisory Group, and the founder of the National Rongxiang Xu foundation and Human Heritage Project. Kevin also receive the Empact 100 recognition at United Nation Headquarter. Kevin serves on the board of the Asian Advisory Board of the USC Davis School of gerontology and Board member of Dr. Rongxiang xu center of regenerative therapeutic at Beth Israel Deaconess Medical center in Harvard Medical school. He earned his BA in neuroscience at USC.
Who is your hero?
My father has been through a lot while seeking the savior of mankind through regenerative life science. He decided to relinquish many things in his life to pursue this. Unlike many other scientists, in the process of researching and developing his own science, he refused numerous enticing offers from others in order to keep the science completely independent. These early decisions eventually led to our current unique circumstance. I am able to hold the science independently and control the direction and scope of its development without worrying about its ownership or freedom of operation.
What’s the single best piece of business advice that helped shape who you are as an entrepreneur today, and why?
When you are running a life-science based corporation, you need to make sure you understand your intellectual property in depth, and how to maintain 100 percent ownership of it to stay in a protective position before making any future developments. For example, a newly created technology will encounter many rounds of dilution through finance and expansion. You have to make sure you do not lose the control of the intellectual property and fully understand the potential of the owned technology before proceeding.
What’s the biggest mistake you ever made in your business, and what did you learn from it that others can learn from too?
If you look into the current field of the biotechnology industry, two potential mistakes you can make quickly emerge. First, a biotechnology holding promising patents is sold to a big pharmaceutical company at an early stage, but ends up being put on hold. It’s taken off the shelf for development and remains inactive, never making it to application. In the second scenario, an early-stage biotech company allows many investors to share the company — with too many shares given out — and faces difficulties expanding its technology later on due to the loss of dominant ownership control.